A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 25 - 65 |
| Updated: | 6/29/2018 |
| Start Date: | April 25, 2017 |
| End Date: | May 2019 |
| Contact: | Johanna Sonnenschein, BA |
| Email: | j.sonnenschein@wustl.edu |
| Phone: | 314-747-2627 |
Bariatric surgery markedly improves glycemic control in persons with T2D. Roux-en-Y gastric
bypass (RYGB), a procedure that bypasses the upper gastrointestinal (UGI) tract, results in
greater rates of diabetes resolution compared to methods that leave the UGI tract intact.
Studies suggest that mechanisms beyond weight-loss account for the superiority of RYGB
compared to other surgical methods. These weight-loss independent metabolic effects may
involve increased postprandial production and release of nutrition- responsive hormones.
Fibroblast growth factor 21 (FGF21) is a nutrition-adaptive hormone with the potential to
alleviate symptoms of diabetes and obesity. Preliminary data therefore suggest that RYGB
surgery may alter postprandial FGF21 regulation which could be important for achieving
post-meal nutrient homeostasis. Therefore, the goal of this study is to test how nutrient
content of the meal affects FGF21 concentrations before and after weight loss induced by RYGB
or very low calorie diet (VLCD) therapy. The importance of FGF21 for glucose, insulin,
triglyceride, and adipose tissue and muscle metabolism in these two groups will also be
tested.
bypass (RYGB), a procedure that bypasses the upper gastrointestinal (UGI) tract, results in
greater rates of diabetes resolution compared to methods that leave the UGI tract intact.
Studies suggest that mechanisms beyond weight-loss account for the superiority of RYGB
compared to other surgical methods. These weight-loss independent metabolic effects may
involve increased postprandial production and release of nutrition- responsive hormones.
Fibroblast growth factor 21 (FGF21) is a nutrition-adaptive hormone with the potential to
alleviate symptoms of diabetes and obesity. Preliminary data therefore suggest that RYGB
surgery may alter postprandial FGF21 regulation which could be important for achieving
post-meal nutrient homeostasis. Therefore, the goal of this study is to test how nutrient
content of the meal affects FGF21 concentrations before and after weight loss induced by RYGB
or very low calorie diet (VLCD) therapy. The importance of FGF21 for glucose, insulin,
triglyceride, and adipose tissue and muscle metabolism in these two groups will also be
tested.
Inclusion Criteria:
Surgery Group (RYGB):
- Males and Females
- Scheduled for RYGB surgery
- Body Mass Index 35-55 kg/m²
- 25-65 years of age
- Without Type II Diabetes
VLCD group:
- Males and Females
- Body Mass Index 35-55 kg/m²
- 25-65 years of age
- Without Type II Diabetes
Exclusion Criteria:
Surgery Group (RYGB):
- Regular use of tobacco products
- Previous intestinal resection
- Pregnant or breastfeeding
- Evidence of significant organ system dysfunction or disease other than obesity and T2D
- Use of any medication that might, in the opinion of the investigator, affect metabolic
function
- Exercise ≥90 minutes per week
- Use or past use of hormone replacement therapy within the past 6 months
VLCD Group:
- Regular use of tobacco products
- Previous intestinal resection
- Pregnant or breastfeeding
- Evidence of significant organ system dysfunction or disease other than obesity and T2D
- Use of any medication that might, in the opinion of the investigator, affect metabolic
function
- Exercise ≥90 minutes per week
- Use or past use of hormone replacement therapy within the past 6 months
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Phone: 314-747-2627
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
